Odyssey Therapeutics Inc. closed a hefty $168 million series B round to progress multiple small-molecule and protein-based drug discovery and development programs in autoimmune disease and cancer.
About 50% of patients with lung cancer present with metastatic disease; researchers have shown that breast cancer metastasis-suppressor 1 (BRMS1) suppresses metastases in non-small-cell lung cancer and other solid tumors due to its ability to function in a multiprotein histone deacetylase transcriptional corepressor complex or as an E3 ligase to control the degradation of p300 acetyltransferase.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to epidermal growth factor receptor (EGFR)-binding moiety through linker reported to be useful for the treatment of cancer.
Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.
Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.
Vividion Therapeutics Inc. has signed a potential $930 million deal with Tavros Therapeutics Inc., focused on finding four cancer targets using the latter’s technology that aims to exploit weaknesses in tumor cells and cause them to self-destruct.
It was a busy day at Moderna Inc. as Merck & Co. Inc. exercised its option to jointly develop and commercialize a personalized cancer vaccine with Moderna in a deal the two companies inked in 2016. Moderna also notched another emergency use authorization (EUA) for its COVID-19 vaccine, this one targeting the omicron variant, for use by those under age 18.
RSS
